FDA approves Roivant's LISRAYA (brepocitinib) for dermatomyositis at $35K WAC

Roivant Sciences Ltd.

FDA granted approval of LISRAYA (brepocitinib) for adult dermatomyositis on Aug 28, 2026.
Wholesale acquisition cost set at $35,000 per 30-count bottle of 30 mg tablets.
No additional financial or commercial launch details disclosed in the filing.

item 8.01 item 9.01

Roivant Sciences Ltd. filing history →

Source: SEC EDGAR

accession 0001140361-26-034854

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.